drugset
drugset / Trial / NCT05010525

A Study to Assess the Safety, Pharmacokinetics, and Preliminary Efficacy of ATG 016 Monotherapy in Patients With Advanced Solid Tumors

NCT05010525 ↗

Phase 1/2 Terminated 8 enrolled Antengene Corporation
Non-randomizedParallel-groupOpen-labelTreatment

Summary

This is A Phase Ib/II Study to Assess the Safety, Pharmacokinetics, and Preliminary Efficacy of ATG 016 Monotherapy in Patients with Advanced Solid Tumors

Timeline

Start
2021-09-01
Primary completion
2022-11-14
Completion
2022-11-14

Outcome

Outcome not reported

Stopped (Business): “Based on the adjustment of clinical research and development strategy，sponsor decided to terminate the study”

Drugs

EvaluationDrugModalityDoseRoute
Subject ATG-016 Unknown 20 mg Oral
Subject ATG-016 Unknown 35 mg Oral
Subject ATG-016 Unknown 50 mg Oral
Subject ATG-016 Unknown 65 mg Oral

Indications

cancer